Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Terrazzan has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial Intelligence and Virtual Screening to Identify Small Molecules Inhibiting Transglutaminase 2 for Investigation and Treatment of Breast Cancer

    by Carlo M. Bergamini, Niel M. Henriksen, Brianna Ryan, Taylor A. Prince, Anna Terrazzan, Pietro Ancona, Cristina Zuccato, Gianluca Aguiari, Valentina Rosta, Jeffrey W. Keillor, et al.

    Artificial intelligence‐assisted virtual screening enables identification of chemically diverse bioactive small molecules. We targeted transglutaminase 2 (TG2), a multifunctional protein associated with mesenchymal‐like features in breast cancer. Approximately 10 million compounds were screened against the catalytic site of open TG2 using the AtomNet structure‐based deep‐learning model. The top 30,000 candidates underwent physicochemical and structural filtering, diversity clustering, and manual selection, yielding 84 compounds for experimental evaluation. Fourteen induced apoptosis in MCF‐7, eight retained activity in MDA‐MB‐436, and three in MDA‐MB‐231 cells, also reducing transamidase activity in cellular lysates. Chemical‐space and fingerprint analyses placed C10 , C12, and G11 outside the principal clusters of known active TG2 inhibitors, identifying structurally differentiated, nonpeptidic scaffolds. Docking into open and intermediate TG2 conformations consistently ranked G11 as the most favorable candidate, with predicted binding near the catalytic core. In a 5‐(biotinamido)pentylamine (5‐BAP‐based assay, G11 inhibited purified recombinant human TG2 with an IC 50 of 7.64 ± 2.87 μM, while an independent dimethyl casein–dansyl cadaverine assay confirmed concentration‐dependent inhibition and yielded an estimated K i of 44 ± 11 μM, assuming competitive inhibition with respect to the substrate. Finally, G11 did not significantly affect the viability of HEK293 cells, which express negligible or very low levels of TG2.

  • Open Access

    MicroRNAs and predicted targets in the switch from monolayered to spheroids of cholangiocarcinoma cells

    by Leda Roncoroni, Anna Terrazzan, Luca Elli, Pietro Ancona, Paula Olaizola, Silvia Tabano, Patrizia Colapietro, Filippo Gamberini, Chiara Orlandi, Gianluca Aguiari, et al.

  • Open Access

    Precision single-cell profiling of Circulating Tumour Cells: novel markers and data-driven characterization by CTCeek

    by Anna Terrazzan, Pietro Ancona, Francesca P. Carbone, Pachara Trevisan, Cristina Zuccato, Ewa A. Szymanek, Michał Szeląg, Federica Brugnoli, Anna Żaczek, Pawel Gaj, et al.

    Circulating tumour cells (CTCs) represent a minimally invasive method for monitoring cancer evolution in patients. CTCs are nowadays commonly isolated using antibodies against EPCAM protein. A key limitation regards the extent of EPCAM-negative CTCs, such as those that undergo EMT or whose tumour of origin is EPCAM-low or negative. We studied 3,302 RNA single-cell transcriptomes reported as CTCs in public repositories. Using copy number variation and cell type-specific markers, we discriminated bona fide CTCs from contaminating blood cells, often mislabelled as CTCs. The integration of bona fide CTCs and PBMCs, from multiple datasets, allowed us to identify novel markers, such as CLDN4, CLDN7, EFNA1 and TACSTD2 for epithelial CTCs, KCNK15 and LY6K for epithelial B CTCs, and ITGB4 for both epithelial B and mesenchymal CTCs. We revealed PODXL, AXL, CAV1, and TGM2 as markers of mesenchymal CTCs, which might be undetectable using anti-EPCAM antibodies, and TM4SF1 as universal marker, expressed in all CTC subclasses. Additionally, we found platelets to be physically associated with the epithelial A, but not with the epithelial B or the mesenchymal subtypes. Finally, we developed and implemented CTCeek, the first web-based and public reference tool that automatically annotates bona fide CTCs from scRNA-sequencing profiles.

  • Open Access

    Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K+ voltage-dependent Kv2.1 channel

    by Rita Canella, Anna Terrazzan, Francesca P. Carbone, Silvia Grassilli, Carlo M. Bergamini, Valeria Bertagnolo, Federica Brugnoli, Pietro Ancona, Nicoletta Bianchi

    We have investigated the involvement of K + channels in generating the membrane current in MDA-MB-436 cells, a model of triple-negative breast cancer (TNBC). The membrane current is strongly influenced by the opening of voltage-dependent channels insensitive to the nonspecific K + channel inhibitor 4-aminopyridine (4-AP). Using the cell patch clamp technique, we observed a significant decrease in membrane current after exposure to the generic K + channel inhibitor tetraethylammonium chloride (TEA-Cl), indicating that K + ions contribute to the overall membrane current through K + channels that are insensitive to 4-AP but TEA-Cl-sensitive. RNA-sequencing analysis identified the Big Potassium (BK or Maxi-K or KCa1.1, encoded by KCNMA1 ) and the Kv2.1 (encoded by KCNB1 ) channels as putative candidates, both of which are involved in cancer cell proliferation and migration. Iberiotoxin, a specific inhibitor of BK channels, did not affect the total membrane current, just as CdCl₂ did, a potent inhibitor of Ca 2 ⁺ channels involved in BK activation. Using selective inhibitors, stromatoxin and drofenine, we demonstrated that the Kv2.1 channel contributes to the membrane current in MDA-MB-436 cells. Furthermore, drofenine inhibited cell migration as measured by the xCELLigence Real-Time Cell Analyzer System and induced apoptosis. Single-cell analysis revealed that the Kv2.1 channel is expressed in both normal and cancerous tissues, with significant upregulation in brain metastases. This raises the possibility that Kv2.1 could be explored as a potential therapeutic target for controlling advanced stages of the neoplasia.

  • Open Access

    Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer

    by Francesca Pia Carbone, Pietro Ancona, Stefano Volinia, Anna Terrazzan, Nicoletta Bianchi

    Mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with the triple-negative breast cancer phenotype, particularly aggressive and hard-to-treat tumors lacking estrogen, progesterone, and human epidermal growth factor receptor 2. This research aimed to understand the metabolic and genetic links behind BRCA1 and BRCA2 mutations and investigate their relationship with effective therapies. Using the Cytoscape software, two networks were generated through a bibliographic analysis of articles retrieved from the PubMed-NCBI database. We identified 98 genes deregulated by BRCA mutations, and 24 were modulated by therapies. In particular, BIRC5, SIRT1, MYC, EZH2, and CSN2 are influenced by BRCA1, while BCL2, BAX, and BRIP1 are influenced by BRCA2 mutation. Moreover, the study evaluated the efficacy of several promising therapies, targeting only BRCA1/BRCA2-mutated cells. In this context, CDDO-Imidazolide was shown to increase ROS levels and induce DNA damage. Similarly, resveratrol decreased the expression of the anti-apoptotic gene BIRC5 while it increased SIRT1 both in vitro and in vivo. Other specific drugs were found to induce apoptosis selectively in BRCA-mutated cells or block cell growth when the mutation occurs, i.e., 3-deazaneplanocin A, genistein or daidzein, and PARP inhibitors. Finally, over-representation analysis on the genes highlights ferroptosis and proteoglycan pathways as potential drug targets for more effective treatments.


  • Open Access

    Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites

    by Mariana Gallo, Elena Ferrari, Federica Brugnoli, Anna Terrazzan, Pietro Ancona, Stefano Volinia, Valeria Bertagnolo, Carlo M. Bergamini, Alberto Spisni, Thelma A. Pertinhez, et al.

    Breast Cancer (BrCa) exhibits a high phenotypic heterogeneity, leading to the emergence of aggressive clones and the development of drug resistance. Considering the BrCa heterogeneity and that metabolic reprogramming is a cancer hallmark, we selected seven BrCa cell lines with diverse subtypes to provide their comprehensive metabolome characterization: five lines commonly used (SK-Br-3, T-47D, MCF-7, MDA-MB-436, and MDA-MB-231), and two patient-derived xenografts (Hbcx39 and Hbcx9). We characterized their endometabolomes using 1H-NMR spectroscopy. We found distinct metabolite profiles, with certain metabolites being common but differentially accumulated across the selected BrCa cell lines. High levels of glycine, lactate, glutamate, and formate, metabolites known to promote invasion and metastasis, were detected in all BrCa cells. In our experiment setting were identified unique metabolites to specific cell lines: xanthine and 2-oxoglutarate in SK-Br-3, 2-oxobutyrate in T-47D, cystathionine and glucose-1-phosphate in MCF-7, NAD+ in MDA-MB-436, isocitrate in MDA-MB-231, and NADP+ in Hbcx9. The unique and enriched metabolites enabled us to identify the metabolic pathways modulated in a cell-line-specific manner, which may represent potential candidate targets for therapeutic intervention. We believe this study may contribute to the functional characterization of BrCa cells and assist in selecting appropriate cell lines for drug-response studies.


  • Open Access

    Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors

    by Pietro Ancona, Alessandro Trentini, Anna Terrazzan, Silvia Grassilli, Pauline Navals, Eric W.J. Gates, Valentina Rosta, Carlo Cervellati, Carlo M. Bergamini, Angela Pignatelli, et al.


  • Open Access

    Protein Kinase C at the Crossroad of Mutations, Cancer, Targeted Therapy and Immune Response

    by Angelo Aquino, Nicoletta Bianchi, Anna Terrazzan, Ornella Franzese

    The frequent PKC dysregulations observed in many tumors have made these enzymes natural targets for anticancer applications. Nevertheless, this considerable interest in the development of PKC modulators has not led to the expected therapeutic benefits, likely due to the complex biological activities regulated by PKC isoenzymes, often playing ambiguous and protective functions, further driven by the occurrence of mutations. The structure, regulation and functions of PKCs have been extensively covered in other publications. Herein, we focused on PKC alterations mostly associated with complete functional loss. We also addressed the modest yet encouraging results obtained targeting PKC in selected malignancies and the more frequent negative clinical outcomes. The reported observations advocate the need for more selective molecules and a better understanding of the involved pathways. Furthermore, we underlined the most relevant immune mechanisms controlled by PKC isoforms potentially impacting the immune checkpoint inhibitor blockade-mediated immune recovery. We believe that a comprehensive examination of the molecular features of the tumor microenvironment might improve clinical outcomes by tailoring PKC modulation. This approach can be further supported by the identification of potential response biomarkers, which may indicate patients who may benefit from the manipulation of distinctive PKC isoforms.


  • Open Access

    Inverse Impact of Cancer Drugs on Circular and Linear RNAs in Breast Cancer Cell Lines

    by Anna Terrazzan, Francesca Crudele, Fabio Corrà, Pietro Ancona, Jeffrey Palatini, Nicoletta Bianchi, Stefano Volinia

    Altered expression of circular RNAs (circRNAs) has previously been investigated in breast cancer. However, little is known about the effects of drugs on their regulation and relationship with the cognate linear transcript (linRNA). We analyzed the dysregulation of both 12 cancer-related circRNAs and their linRNAs in two breast cancer cell lines undergoing various treatments. We selected 14 well-known anticancer agents affecting different cellular pathways and examined their impact. Upon drug exposure circRNA/linRNA expression ratios increased, as a result of the downregulation of linRNA and upregulation of circRNA within the same gene. In this study, we highlighted the relevance of identifying the drug-regulated circ/linRNAs according to their oncogenic or anticancer role. Interestingly, VRK1 and MAN1A2 were increased by several drugs in both cell lines. However, they display opposite effects, circ/linVRK1 favors apoptosis whereas circ/linMAN1A2 stimulates cell migration, and only XL765 did not alter the ratio of other dangerous circ/linRNAs in MCF-7. In MDA-MB-231 cells, AMG511 and GSK1070916 decreased circGFRA1, as a good response to drugs. Furthermore, some circRNAs might be associated with specific mutated pathways, such as the PI3K/AKT in MCF-7 cells with circ/linHIPK3 correlating to cancer progression and drug-resistance, or NHEJ DNA repair pathway in TP-53 mutated MDA-MB-231 cells.


  • Open Access

    Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways

    by Francesca Crudele, Nicoletta Bianchi, Anna Terrazzan, Pietro Ancona, Antonio Frassoldati, Paolo Gasparini, Adamo P. D’adamo, Dimitrios Papaioannou, Ramiro Garzon, Anna Wójcicka, et al.

    CircRNAs constitute a novel class of RNA, generally considered as non-coding RNAs; nonetheless, their coding potential has been under scrutiny. In this work, we systematically explored the predicted proteins of more than 160,000 circRNAs detected by exome capture RNA-sequencing and collected in the MiOncoCirc pan-cancer compendium, including normal and cancer samples from different types of tissues. For the functional evaluation, we compared their primary structure and domain composition with those derived from the same linear mRNAs. Among the 4362 circRNAs potentially encoding proteins with a unique primary structure and 1179 encoding proteins with a novel domain composition, 183 were differentially expressed in cancer. In particular, eight were associated with prognosis in acute myeloid leukemia. The functional classification of the dysregulated circRNA-encoded polypeptides showed an enrichment in the heme and cancer signaling, DNA-binding, and phosphorylation processes, and disclosed the roles of some circRNA-based effectors in cancer.